Table 1

Validation of NBL and NICE algorithms11 in cohorts of children presenting with non-blanching rash

Centre. No. of casesNo. treated (%)No. with confirmed or probable MCD (%) (No. confirmed)% of those Rx who had MCDNo. identified for treatment by the NBL algorithm (%)No. identified for treatment by the NICE algorithm (%)
Retrospective cohorts
1. n=230153 (66)83 (37) {72}5490 (39)159* (69)
2. n=5621 (38)13 (23) {8}6220 (36)31 (55)
3. n=4326 (60)3 (7) {1}1218 (42)31 (72)
Pilot cohorts
4a. n=7748 (62)14 (18) {7}2935 (46)44 (57)
5. n=42 8 (19) 2 (5) {2}258 (19)19 (45)
6. n=3920 (51) 9 (23) {7}4520 (51)23* (59)
7. n=189 (50) 1 (6) {1}119 (50)11(61)
Prospective cohort
4b. n=12039 (33)20 (17) {9}5131 (26)64* (53)
Total; 625324 (52)145 {107}231 (37)382 (61)
  • *Four children with probable MCD not identified by the NICE algorithm.

  • MCD, meningococcal disease; NBL, Newcastle-Birmingham-Liverpool; NICE, National Institute for Health and Care Excellence. Rx, treated.